New schizophrenia drug shows promise in 6-week trial
NCT ID NCT02477020
First seen May 11, 2026 · Last updated May 18, 2026 · Updated 2 times
Summary
This study tested whether a new drug called TAK-063 can help reduce symptoms of schizophrenia during a sudden worsening (acute exacerbation). 164 adults took either the drug or a placebo for 6 weeks. The main goal was to see if symptoms improved, measured by a standard rating scale. The trial is now complete.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Springdale, Alaska, United States
-
Study site
Culver City, California, United States
-
Study site
Lemon Grove, California, United States
-
Study site
Long Beach, California, United States
-
Study site
Pico Rivera, California, United States
-
Study site
Lauderhill, Florida, United States
-
Study site
Orlando, Florida, United States
-
Study site
Atlanta, Georgia, United States
-
Study site
Lake Charles, Louisiana, United States
-
Study site
St Louis, Missouri, United States
-
Study site
Las Vegas, Nevada, United States
-
Study site
Oklahoma City, Oklahoma, United States
-
Study site
Austin, Texas, United States
-
Study site
Dallas, Texas, United States
-
Study site
Houston, Texas, United States
Conditions
Explore the condition pages connected to this study.